Home/Filings/4/0001415889-18-001121
4//SEC Filing

Spoor Johan M. 4

Accession 0001415889-18-001121

CIK 0001604191other

Filed

Jul 15, 8:00 PM ET

Accepted

Jul 16, 9:08 PM ET

Size

5.6 KB

Accession

0001415889-18-001121

Insider Transaction Report

Form 4
Period: 2018-07-12
Spoor Johan M.
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    2018-07-12+200,000300,034 total
Holdings
  • Common Stock

    (indirect: By Children)
    39,851
Footnotes (1)
  • [F1]Represents grant of restricted stock. Shares shall vest in increments as follows: (i) 1/6 upon the acceptance of a U.S. IND for MS 1819; (ii) 1/6 upon the the first CF patient dosed with MS1819 anywhere in the globe; (iii) 1/6 upon upon enrollment of the first 30 patients in a CF trial; (iv) 1/6 on July 12, 2019; (v) 1/6 on July 12, 2020; and (vi) 1/6 on July 12, 2021.

Issuer

AzurRx BioPharma, Inc.

CIK 0001604191

Entity typeother

Related Parties

1
  • filerCIK 0001535289

Filing Metadata

Form type
4
Filed
Jul 15, 8:00 PM ET
Accepted
Jul 16, 9:08 PM ET
Size
5.6 KB